Summary

The pharmaceutical industry has a reputation as being risk averse to embracing new technologies and spent many years in “watch and wait” mode regarding artificial intelligence (AI). Compared to other industries, pharma has been slow to adopt AI, but there has been increased activity over the past few years. This case study provides an overview of how AI is currently being implemented by the pharmaceutical industry in supply chains and in sales and marketing.


Key Highlights

  • Pharma has been slow to adopt AI, but increased activity has been seen since 2019. Pharma also plans to invest in AI in the near future.
  • While COVID-19 may have temporarily shifted investment away from AI, it could actually lead to increased AI adoption.
  • AI will play a key role in the factories of the future.
  • AI can help marketing become more targeted and personalized, which has shown to be crucial during the COVID-19 pandemic.
  • Harnessing the benefits of AI requires pharma companies to navigate a series of practical and ethical challenges.




Scope

This case study includes -

  • Examples of pharma companies leading the integration of AI into their operations
  • Examples of partnerships between Big Pharma and AI start-ups
  • Examples of other AI initiatives by pharma, including chatbots for patient engagement and enhancing supply chains




Reasons To Buy

  • Develop business strategies by understanding how AI is being used in the biopharmaceutical industry today and how the technology is expected to affect the sector in the future.
  • Stay up to date on the key players in the AI space in drug development and clinical trials.
  • See what activities biopharmaceutical companies are undertaking in the space.
  • Identify opportunities for partnerships with AI vendors.